[
    [
        {
            "time": "2018-11-20",
            "original_text": "IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
            "features": {
                "keywords": [
                    "Class Action",
                    "AbbVie Inc.",
                    "Investor Alert"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-20",
            "original_text": "SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018",
            "features": {
                "keywords": [
                    "Class Action",
                    "AbbVie Inc.",
                    "Shareholder Alert"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-11-20",
            "original_text": "SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV",
            "features": {
                "keywords": [
                    "Class Action",
                    "AbbVie Inc.",
                    "Securities"
                ],
                "sentiment_score": -0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-31",
            "original_text": "Pfizer’s Earnings Quality and Dividend Performance",
            "features": {
                "keywords": [
                    "Earnings Quality",
                    "Dividend Performance",
                    "Pfizer"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pfizer’s Earnings Quality and Dividend Performance",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-15",
            "original_text": "Peek Under The Hood: EQWL Has 10% Upside",
            "features": {
                "keywords": [
                    "Upside",
                    "EQWL"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Peek Under The Hood: EQWL Has 10% Upside",
                "Correlation": 4,
                "Sentiment": 8,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-09-25",
            "original_text": "Gilead Sciences' Latest Tactic? Go Generic",
            "features": {
                "keywords": [
                    "Gilead Sciences",
                    "Generic",
                    "Tactic"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Gilead Sciences' Latest Tactic? Go Generic",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]